CannaGreed.com News Commentary – Analysts have estimated the hemp-CBD market to hit 22 billion by 2022, as consumers around the world increasingly looking to CBD oils, edibles, and other products to help treat chronic pain conditions and as a potential preventative measure for muscle soreness and inflammation.
American’s positive attitude toward the legalization of cannabis could be beneficial for publicly traded companies in the Cannabis/CBD space such as EnviroTechnologies International, Inc. (OTC: ETII), CV Sciences Inc (OTC: CVSI) and Potnetwork Holdings, Inc. (OTC: POTN)
EnviroTechnologies International, Inc. (OTC: ETII), a publicly traded company based in Utah, with already one foot in the Cannabis industry with it’s proprietary and patent-pending machines that produce electrolyzed oxidative fluids (EO Equipment), could be the right choice for both short and long term cannabis investors.
The company recently announced that it was preparing to introduce new technology to licensed cannabis growers in the northwest that will help eliminate growth-impeding pathogens and stimulate harvest yields.
The positive effects and growing acceptance of medicinal hemp, CBD and other cannabis products have been widely discussed in all news venues. The passage of the Farm Act late last year greatly expanded the development and distribution of CBD and hemp products nationwide.
“What hasn’t been covered as much is the potential and existence of fungal and contaminants that are prevalent in nearly all phases of plant growth, harvest, and post-harvest product processing of hemp and cannabis,” said Gaylord Karren, ETI’s President. “Mold and fungal presence in grow rooms as well as outside grow facilities is not only dangerous but also negatively affects the plant’s growth cycle, killing large portions of the crop and leaving bacterial residue on the plants and facilities. This reduces the growth and the ultimate yield. The problem is that there is no real non-toxic solution to eliminate mold and fungal growth in grow facilities. ETI has the only real, effective, non-toxic solution to cleaning and sanitizing plant facilities.”
Last week, EnviroTechnologies International, Inc. reported estimated 2018 revenues and First Quarter equipment orders under contract.
“We expected 2018 to be, primarily, a research and development year as we completed design and technical upgrades to our proprietary and patent-pending machines that produce electrolyzed oxidative fluids (EO Equipment), used by our customers in the carpet-cleaning, agriculture, food service and other related and unrelated industries. We anticipated contracts on or new EO Machines to begin Second Quarter 2019,” said Gaylord Karren ETI’s President.
“First Quarter, 2019 revenues will be approximately $605,000 and contracts for Second Quarter, 2019 are expected to be $885,000.”
CV Sciences, Inc. (OTC: CVSI) operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company also engages in the development, manufacture, marketing, and sale of consumer products containing plant-based CBD under the PlusCBD Oil name in various market sectors, including nutraceutical, beauty care, specialty foods, and vape.
The company recently announced its certification by the US Hemp Authority™ Guidance Program.
This achievement illustrates the Company’s robust quality management system throughout its supply chain from seed to shelf. This certification is a milestone indicative of the Company’s commitment to assuring that customers continue to receive the highest quality products from CV Sciences and that all PlusCBD Oil™ products are safe. Additionally, this certification should give law enforcement officials certainty that the company’s products are not made from genetic strains of marijuana.
Last month, Diamond CBD Inc.,wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC: POTN) announced that it is presenting its popular line of Diamond CBD oils, edibles, and creams to several large pharmacy chains.
“Our array of CBD products already play an active role in the wellness routine of thousands of Americans,” said Kevin Hagen, CEO of Diamond CBD parent company PotNetwork Holdings, Inc. “That’s why we are happy to present the benefits of CBD and our popular oils, edibles and beauty products to several large pharmacy chains in the days ahead.”
Contents published in this website contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CannaGreed undertakes no obligation to update such statements. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company.